Kim Mijeong, Singh Manjot, Lee Bum-Kyu, Hibbs Moira, Richardson Kirsty, Ellies Lesley, Wintle Larissa, Stuart Lisa M, Wang Jenny Y, Voon Dominic C, Blancafort Pilar, Wang Jianlong, Kim Jonghwan, Leedman Peter J, Woo Andrew J
Department of Molecular Biosciences, The University of Texas at Austin, Austin, TX, 78712, USA.
Harry Perkins Institute of Medical Research, QEII Medical Centre, Nedlands and Centre for Medical Research, The University of Western Australia, Perth, WA, 6000, Australia.
Oncogenesis. 2022 Oct 7;11(1):60. doi: 10.1038/s41389-022-00435-1.
The MYC proto-oncogene (MYC) is one of the most frequently overexpressed genes in breast cancer that drives cancer stem cell-like traits, resulting in aggressive disease progression and poor prognosis. In this study, we identified zinc finger transcription factor 148 (ZNF148, also called Zfp148 and ZBP-89) as a direct target of MYC. ZNF148 suppressed cell proliferation and migration and was transcriptionally repressed by MYC in breast cancer. Depletion of ZNF148 by short hairpin RNA (shRNA) and CRISPR/Cas9 increased triple-negative breast cancer (TNBC) cell proliferation and migration. Global transcriptome and chromatin occupancy analyses of ZNF148 revealed a central role in inhibiting cancer cell de-differentiation and migration. Mechanistically, we identified the Inhibitor of DNA binding 1 and 3 (ID1, ID3), drivers of cancer stemness and plasticity, as previously uncharacterized targets of transcriptional repression by ZNF148. Silencing of ZNF148 increased the stemness and tumorigenicity in TNBC cells. These findings uncover a previously unknown tumor suppressor role for ZNF148, and a transcriptional regulatory circuitry encompassing MYC, ZNF148, and ID1/3 in driving cancer stem cell traits in aggressive breast cancer.
MYC原癌基因(MYC)是乳腺癌中最常过度表达的基因之一,它驱动癌症干细胞样特征,导致疾病进展迅速且预后不良。在本研究中,我们鉴定出锌指转录因子148(ZNF148,也称为Zfp148和ZBP - 89)是MYC的直接靶点。ZNF148抑制细胞增殖和迁移,并且在乳腺癌中被MYC转录抑制。通过短发夹RNA(shRNA)和CRISPR/Cas9敲低ZNF148可增加三阴性乳腺癌(TNBC)细胞的增殖和迁移。对ZNF148的全转录组和染色质占据分析揭示了其在抑制癌细胞去分化和迁移中的核心作用。从机制上来说,我们鉴定出DNA结合抑制因子1和3(ID1、ID3),即癌症干性和可塑性的驱动因子,是ZNF148转录抑制作用之前未被发现的靶点。敲低ZNF148可增加TNBC细胞的干性和致瘤性。这些发现揭示了ZNF148此前未知的肿瘤抑制作用,以及在侵袭性乳腺癌中由MYC、ZNF148和ID1/3组成的驱动癌症干细胞特征的转录调控回路。